Stockscreener 앱 받기
1.7988
3.76%
0.0688
전일 마감가:
$1.73
열려 있는:
$1.74
하루 거래량:
149.49K
Relative Volume:
0.19
시가총액:
$76.79M
수익:
-
순이익/손실:
$-25.80M
주가수익비율:
-2.9013
EPS:
-0.62
순현금흐름:
$-22.19M
1주 성능:
+1.99%
1개월 성능:
-70.18%
6개월 성능:
-71.05%
1년 성능:
-69.10%
1일 변동 폭
$1.74
$1.82
1주일 범위
$1.66
$1.83
52주 변동 폭
$1.40
$11.67
Essa Pharma Inc Stock (EPIX) Company Profile
명칭
Essa Pharma Inc
전화
(778) 331-0962
주소
SUITE 720, VANCOUVER, BC
EPIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| EPIX | 1.79 | 76.79M | 0 | -25.80M | -22.19M | -0.62 |
| VRTX | 450.09 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.09 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.68 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.62 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Essa Pharma Inc Stock (EPIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2021-03-04 | 개시 | Piper Sandler | Overweight |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2019-10-25 | 개시 | Oppenheimer | Outperform |
Essa Pharma Inc 주식(EPIX)의 최신 뉴스
Piper Sandler Downgrades ESSA Pharma (EPIX) - MSN
United States shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
Thinking about buying stock in Adverum Biotechnologies, Roma Gre - GuruFocus.com
Oppenheimer Downgrades ESSA Pharma (EPIX) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc.EPIX - PR Newswire
PFM Health Sciences, LP Adjusts Stake in ESSA Pharma Inc - GuruFocus.com
RTW INVESTMENTS, LP Acquires Shares in ESSA Pharma Inc - GuruFocus.com
ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
ESSA Pharma And 2 Other US Penny Stocks To Watch - Yahoo Finance
Jones Trading Downgrades ESSA Pharma (EPIX) - MSN
ESSA Pharma (NASDAQ:EPIX) Lowered to Market Perform Rating by Oppenheimer - Defense World
ESSA Pharma (NASDAQ:EPIX) Rating Lowered to Neutral at Piper Sandler - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Growth N. V. Biotech Sells 7,879,583 Shares of ESSA Pharma Inc. (NASDAQ:EPIX) Stock - MarketBeat
Bb biotech ag sells Essa Pharma shares for $12 million - Investing.com
Bb biotech ag sells Essa Pharma shares for $12 million By Investing.com - Investing.com UK
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ESSA Pharma shares downgraded after halting drug development By Investing.com - Investing.com Canada
ESSA Pharma terminates vital trial, leading Piper Sandler to cut shares rating - Investing.com Canada
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials - Investing.com Canada
Jefferies Financial Group Downgrades ESSA Pharma (NASDAQ:EPIX) to Hold - MarketBeat
2024-11-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect | NDAQ:EPIX | Press Release - Stockhouse Publishing
Michael Jenson, PA-C, on Minnesota Urology’s Surgical Impotence Management Strategy program - Urology Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect - AccessWire
ESSA Pharma tank as it drops Phase II masofaniten study - The Pharma Letter
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
ESSA Pharma stock plunges to 52-week low of $1.55 - Investing.com India
ESSA Pharma stock plunges to 52-week low of $1.55 By Investing.com - Investing.com South Africa
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Essa ends prostate cancer bid, seeks strategic options - BioWorld Online
ESSA Pharma tanks after terminating trial for its prostate cancer treatment - MSN
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results - Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results - Benzinga
ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC - OncLive
Dow Jumps 400 Points; US Adds 12,000 Jobs In October - Benzinga
Jones Trading cuts ESSA Pharma shares to hold from buy on trial data - Investing.com Australia
Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade - Barchart
Why Is ESSA Pharma Stock Plunging On Friday?ESSA Pharma (NASDAQ:EPIX) - Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
ESSA Pharma tanks after terminating trial for its prostate cancer treatment (NASDAQ:EPIX) - Seeking Alpha
Jones Trading cuts ESSA Pharma shares to hold from buy on trial data By Investing.com - Investing.com South Africa
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment - Yahoo Finance
Essa Pharma Shares Drop After Lead Drug Candidate Fails - MarketWatch
ESSA Pharma (NASDAQ:EPIX) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - VictoriaNow
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - StockTitan
When the Price of (EPIX) Talks, People Listen - Stock Traders Daily
ESSA Pharma Insiders Placed Bullish Bets Worth US$709.0k - Yahoo Finance
Essa Pharma Inc (EPIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):